Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Derek Nay"'
Autor:
Rouslan Kotchetkov, Ian R. Drennan, David Susman, Erica DiMaria, Lauren Gerard, Derek Nay, Anca Prica
Publikováno v:
International Journal of Cancer. 152:1884-1893
Bendamustine and rituximab (BR) is a preferred first-line therapy for indolent non-Hodgkin's lymphoma (iNHL) and mantle cell lymphoma (MCL); however, few reports on BR performance in elderly patients are available to date. We compared safety and effi
Publikováno v:
Hematology. 23:596-599
Patients with a single hematological malignancy may be unexpectedly diagnosed with a clonally unrelated synchronous dual hematological malignancy (SDHM). The presence of a secondary hematological malignancy may be overlooked and only identified in si
Publikováno v:
Blood. 138:4519-4519
Background: Bendamustine plus rituximab (B+R) was established as a preferred first-line therapy for indolent non-Hodgkin's lymphoma (iNHL) and mantle cell lymphoma (MCL); however, few reports on the performance of this combination in the real-world s
Publikováno v:
Journal of Clinical Oncology. 39:e19540-e19540
e19540 Background: Bendamustine plus rituximab (B+R) was established as a preferred first line therapy for patients with previously untreated indolent non-Hodgkin’s lymphoma based on the BRIGHT and STIL trials. However, only few reports on efficacy
Autor:
Thomas A. Rado, Danjie Zhang, Wen Shi, Derek Nay, Andrei R. Shustov, Thomas A. Giever, Leonard M. Klein, Alfred Saleh, Jeffrey P. Sharman, Kathryn S. Kolibaba, Andres Forero, Sarit Assouline
Publikováno v:
Blood. 128:2963-2963
Introduction: Entospletinib (GS-9973) is an orally bioavailable, selective inhibitor of spleen tyrosine kinase (Syk). Syk is a mediator of B-cell receptor signaling in normal and transformed B-cells. Targeting the B-cell receptor (BCR)-signaling path
Publikováno v:
Blood. 128:5975-5975
Background: Patients with a single hematological malignancy (SHM) may be unexpectedly diagnosed with a synchronous dual hematological malignancy (SDHM). Management of such patients is challenging and the impact of therapy on the secondary malignancy